Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

Publikation

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

Wissenschaftlicher Artikel/Review - 01.09.2006

Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Jörger Markus, Schellens J H M, Beijnen J H

Zitation

Brouwers E, Tibben M, Rosing H, Hillebrand M, Jörger M, Schellens J, Beijnen J. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of mass spectrometry : JMS 2006; 41:1186-94.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Journal of mass spectrometry : JMS 2006; 41

Veröffentlichungsdatum

01.09.2006

ISSN (Druck)

1076-5174

Seiten

1186-94

Kurzbeschreibung/Zielsetzung

We present a highly sensitive, rapid method for the determination of platinum originating from the anticancer agents cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. The method is based on the quantification of platinum by inductively coupled plasma mass spectrometry and allows quantification of 7.50 ng l-1 platinum in only 150 microl of matrix. Sample pretreatment involves dilution of samples with 1% HNO3. Validation fulfilled the most recent FDA guidelines for bioanalytical method validation. Validated ranges of quantification were 7.50 ng l-1 to 1.00x10(5) ng l-1 in plasma ultrafiltrate for all three platinum compounds. The assay is now successfully used to support pharmacokinetic studies in cancer patients treated with cisplatin, carboplatin, or oxaliplatin.